Loading organizations...
§ Private Profile · Hellerup, Hovedstaden, Denmark
Minervax is a technology company.
MinervaX is engaged in the clinical development of a Group B Streptococcal vaccine targeting pregnant women and older adults.
Minervax has raised $276.9M across 6 funding rounds.
Minervax has raised $276.9M in total across 6 funding rounds.
Minervax has raised $276.9M in total across 6 funding rounds.
Minervax's investors include Vincent Brichard, Tal Zaks, Adjuvant Capital, Industrifonden, LF Invest, Novo Holdings, Pureos Bioventures, Sanofi Ventures, Sunstone Life Science Ventures, Trill Impact, Wellington Partners, Andera Partners.
MinervaX is a clinical-stage biotech company developing a prophylactic vaccine called AlpN GBS against Group B Streptococcus (GBS), a leading cause of life-threatening infections, stillbirths, and disabilities in newborns.[1][2][3][4][5] The vaccine targets maternal immunization to prevent adverse pregnancy outcomes, addressing an estimated 150,000 preventable infant deaths annually, with a protein-only design using fusions of immunogenic GBS surface proteins.[1][3][4][5] Founded in 2010 and based in Copenhagen, Denmark, the company has raised nearly €200M ($143M+), reached Series C stage, and completed Phase II trials in 470 pregnant women across Denmark, the UK, Uganda, and South Africa, positioning it for Phase III advancement.[1][4][5]
MinervaX was founded in 2010 in Copenhagen, Denmark, as a biotech focused on innovative vaccines against GBS, a pathogen causing severe newborn infections.[1][3][5] While specific founders are not detailed in available sources, leadership includes executives with deep vaccine expertise, such as a former CEO of LimmaTech Biologics—a spin-off from GlycoVaxyn, acquired by GSK in 2015—who advanced proprietary platforms and collaborated on related assets.[4] Pivotal early traction came from grants, investor syndicates, and loans totaling nearly €200M, enabling fast-tracked clinical development; key milestones include completing two Phase II trials (MVX0005) in 2023 and expanding labs in Lund for advanced assays and manufacturing.[1][4][5]
MinervaX rides the wave of maternal immunization vaccines, addressing unmet needs in global health where GBS causes ~150,000 preventable newborn deaths yearly, amplified by rising antimicrobial resistance and disparities in low-resource settings.[3][4] Timing aligns with post-pandemic vaccine tech advances and regulatory pushes for pregnancy-focused biologics, as seen in precedents like palivizumab filings.[4] Favorable market forces include grants/loans for neglected diseases and biotech M&A trends (e.g., GSK's past acquisitions), positioning MinervaX to influence neonatal health ecosystems by filling a critical gap—no approved GBS vaccine exists despite decades of need.[1][3][4][5]
MinervaX is primed for Phase III trials and potential commercialization of AlpN GBS, with ongoing manufacturing scale-up and team expansions in clinical, research, and finance to support regulatory filings.[4][5] Trends like AI-driven assays, global health funding, and expanding GBS indications (beyond newborns to adults) will shape its path, potentially leading to partnerships or acquisition by big pharma amid biotech consolidation.[1][4] Its influence could evolve from pioneer to market leader, dramatically cutting global stillbirths and inspiring protein-based vaccine platforms—transforming MinervaX from a high-need innovator into a life-saving standard.[3][4][5]
Minervax has raised $276.9M across 6 funding rounds. Most recently, it raised $57.3M Other Equity in October 2023.